Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.

@article{Chang2014CosteffectivenessOD,
  title={Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.},
  author={Chia-Hsien Chang and Y K Yang and Jyh-Hong Chen and L J Lin},
  journal={Thrombosis research},
  year={2014},
  volume={133 5},
  pages={782-9}
}
BACKGROUND Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done mostly in Western countries. It remains to be seen whether dabigatran will be cost effective in a practice environment where warfarin is significantly underused and the costs of both warfarin and international normalized ration INR monitoring are cheap. METHODS We performed a cost-effectiveness analysis with a Markov model to evaluate the value of dabigatran to prevent stroke and systemic embolism in… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Dabigatran versus warfarin in patients with atrial fibrillation.

The New England journal of medicine • 2009
View 3 Excerpts
Highly Influenced

The lowest effective intensity of anticoagulation for patients with atrial fibrillation and the predictor factors of maintenance dose requirement at a medical center

GM Chou
2006
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…